A federal appeals court has breathed new life into lawsuits against Kenvue, the consumer health company behind Tylenol, reviving claims that the company failed to adequately warn pregnant women about potential risks linked to autism spectrum disorder and ADHD. The decision sent Kenvue shares down 1.4% on Tuesday, even as the broader US healthcare sector edged higher.
What the court actually did
The ruling from the US Court of Appeals for the Second Circuit did not declare Tylenol unsafe or assign any damages. Instead, it overturned a lower court's dismissal of the lawsuits and sent the cases back for further proceedings. This procedural step means the legal battle is far from over—and far from a final verdict on the science.
In legal terms, the appeals court found that the plaintiffs had presented enough evidence to move forward with their argument that Kenvue should have included stronger warnings about prenatal use. The cases will now return to the district court, where both sides will engage in motions, evidence gathering, and debates over expert testimony.
What this means for Kenvue
Kenvue, which was spun off from Johnson & Johnson in 2023, is one of the largest pure-play consumer health companies in the world. Its portfolio includes household names like Tylenol, Motrin, Neutrogena, and Band-Aid. The Tylenol franchise is a significant revenue driver, and any legal overhang can weigh on investor sentiment.
The 1.4% drop in Kenvue's stock reflects the market's sensitivity to litigation risk, even though the company has not been found liable. For context, the broader healthcare sector—tracked by the Health Care Select Sector SPDR Fund (XLV)—rose slightly on the same day, suggesting the move was company-specific rather than sector-wide.
Investors will now watch for the next steps in the legal process. If the cases proceed to trial or if more plaintiffs join, the financial stakes could grow. However, many similar product-liability cases have historically been resolved through settlements or dismissed on scientific grounds.
The science behind the claims
The lawsuits hinge on a contentious area of research: whether acetaminophen, the active ingredient in Tylenol, is linked to neurodevelopmental disorders when taken during pregnancy. Some studies have suggested a possible association, but the evidence is far from conclusive. Major medical organizations, including the American College of Obstetricians and Gynecologists, continue to recommend acetaminophen as a first-line treatment for pain and fever during pregnancy, while advising patients to use the lowest effective dose for the shortest time possible.
The appeals court's decision does not validate the scientific claims—it only allows the legal arguments to proceed. The lower court will now have to weigh expert testimony and scientific evidence before any trial or summary judgment.
What it means for everyday investors
For investors holding Kenvue shares, this ruling introduces a new layer of uncertainty. Litigation can be costly, both in legal fees and potential settlements, and it can distract management from running the business. However, Kenvue is a large, well-capitalized company with a diversified product lineup, and one legal setback does not necessarily spell disaster.
It's also worth noting that the broader healthcare sector remains resilient. Companies in this space often face periodic legal challenges, and the market tends to differentiate between genuine liability risks and procedural developments. The fact that Kenvue's drop was modest and the sector rose suggests that many investors are taking a wait-and-see approach.
For those looking at the bigger picture, this case is a reminder that product-liability risks are part of investing in consumer health stocks. Diversification across sectors and individual holdings can help manage such idiosyncratic risks.
Looking ahead
The legal process will likely take months or even years to play out. Key milestones to watch include the lower court's decisions on motions to dismiss, class certification, and any settlement discussions. Meanwhile, Kenvue's earnings and sales of Tylenol will continue to be driven by seasonal demand and consumer behavior, not just courtroom developments.
In other market news, Silverco Starts Drilling at La Negra, Shares Dip 4.5% as Investors Wait on Results and DocMorris Shares Surge 17% After Deutsche Bank Upgrade on Funding Optimism show how company-specific news can drive stock moves even in a quiet market. Meanwhile, Plus500 Shares Tumble 16% After Full-Year Forecast Fails to Excite Despite Strong First Half highlights the importance of forward guidance in investor sentiment.
For now, Kenvue investors will be watching the legal calendar as closely as the earnings calendar.
